We are pleased to announce that the website maintenance has now been completed and we can again update the site.
You will notice minor changes to the design and layout of the site, but the majority of the work has been on the infrastructure. However, a couple of more obvious changes have been made:
i) Introduction of Quality of Evidence
Quality of Evidence grading has been added to interactions with NNRTIs, NRTIs, raltegravir and maraviroc. Grades will be added to interactions with protease inhibitors over the next few weeks. For further information on this new feature, see the New Alert on the home page.
ii) New Chart Section on Contraceptives/HRT
Contraceptive steroids have been moved from the Steroid section to a new Contraceptive/HRT section. Progestogens are no longer grouped together, but are listed as individual drugs.
